Alimera Sciences News and Activities

Alimera Sciences is owned by ANI Pharmaceuticals.

ANI Pharmaceuticals is one of the...

• Russell 3000;
• TOB Iconic 10,000.

ANI Pharmaceuticals is a company listed under the stock ticker ANIP (US).

ANI Pharmaceuticals has a direct presence in 2 countries.

They are in:

• Biotechnology50%
• Pharmaceuticals50%

Acquisition, funding and merger involving ANI Pharmaceuticals.

• ANI Pharmaceuticals has acquired Alimera Sciences (posted on September 16 2024).
• ANI Pharmaceuticals has announced the acquisition of Alimera Sciences  (posted on June 26 2024).

View the org chart displaying its 14 main executives

Most searched biographies at Alimera Sciences

• Catherine Whittaker-Axon, Associate Director, Regulatory Affairs
• Catherine Griffiths, Associate Director, Market Access and Marketi...
• Robert Townsend, Alliance Manager

Popular executive movements at ANI Pharmaceuticals

• Patrick Walsh, who is Chairman of The Board will soon retire  (posted on December 1 2025).
• Thomas Haughey who is Director, will be promoted to Chairman of the Board  (posted on December 1 2025).

Create your alert
to follow the executive moves at Alimera Sciences.

ANI Pharmaceuticals has 1,915 competitors including Sanofi (France), Moderna (United States (USA)) and Eli Lilly (United States (USA)).

Popular M&A news in Pharmaceuticals

• AbbVie has announced the acquisition of Apogee Therapeutics  (posted on June 23 2026).
• The new name of Stealth BioTherapeutics is Mighty Therapeutics. (posted on June 19 2026).
• Transcend has announced the acquisition of Otsuka America Pharmaceutical  (posted on June 18 2026).

Popular contacts in Pharmaceuticals

• Joaquin Duato - Chief Executive Officer and Chairman of the Board at Johnson & Johnson
• Tracey Franklin - Chief People and Digital Technology Officer at Moderna
• Richard Saynor - Chief Executive Officer at Sandoz

Learn more about the Pharmaceuticals industry

Press releases by Alimera Sciences

• Press Releases | Alimera Sciences Inc.
• Alimera Sciences Reports Record Fourth Quarter and 2019 Results | Alimera Sciences
• Alimera Sciences Meets Revenue Milestone and Accesses Additional $2.5 Million Under Solar Debt Agreement | Alimera Sciences
• Alimera Sciences to Report Fourth Quarter and Full Year 2019 Financial Results on Wednesday, February 26, 2020 and Provide Corporate Update | Alimera Sciences
• Alimera Sciences Refinances Its Debt Facility With Solar Capital | Alimera Sciences
• Alimera Sciences to Participate in the LD Micro 12th Annual Main Event on December 10, 2019 | Alimera Sciences
• Press Releases | Investor Relations | Alimera Sciences
• Alimera Sciences to Participate in the LD Micro 12th Annual Main Event on December 10, 2019 | Alimera Sciences
• Alimera Announces Regulatory Approval for ILUVIEN® in Benelux Countries for The Treatment of Non-Infectious Posterior Uveitis | Alimera Sciences
• Alimera Sciences Announces Effectiveness of Previously Announced Reverse Stock Split | Alimera Sciences
• View more press releases Close

Social media about Alimera Sciences

• Alimera Sciences on Wikipedia, Google News & Yahoo Finance
• Alimera Sciences on LinkedIn, X (Twitter) & YouTube